相关临床试验
11
4 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2005
进行中（未招募）
4
36.4%
已完成
5
45.5%
终止
2
18.2%
暂无批准数据
- Aileron Therapeutics has rebranded to Rein Therapeutics, signaling a sharpened focus on developing treatments for orphan pulmonary and fibrotic diseases. - Rein Therapeutics' lead candidate, LTI-03, is set to enter a Phase 2 clinical trial in the first half of 2025 for the treatment of idiopathic pulmonary fibrosis (IPF). - The company's stock will trade under the new ticker symbol "RNTX" on Nasdaq starting January 13, 2025, marking a new chapter for the company. - Rein Therapeutics' pipeline includes LTI-01, a Phase 2b-ready asset for loculated pleural effusions, holding Orphan Drug and Fast Track Designations.
- Aileron Therapeutics presented Phase 1b trial data for LTI-03 at ICLAF, showing a positive trend in biomarkers related to IPF progression. - The trial observed reduced expression of profibrotic proteins after 14 days of inhaled low-dose LTI-03 (2.5 mg BID) in IPF patients. - Pre-clinical data supports LTI-03's therapeutic potential, demonstrating attenuation of pro-fibrotic proteins and pathways in lung tissue. - Enrollment is complete for Cohort 2 (5 mg BID), with topline data expected soon, evaluating safety, tolerability, and protein biomarkers.
- Aileron Therapeutics presented Phase 1b data on LTI-03 for IPF at ICLAF, showing positive trends in biomarkers related to fibrosis. - Low-dose LTI-03 (2.5 mg BID) demonstrated statistically significant reductions in collagen synthesis, inflammation, and fibrogenesis. - Pre-clinical data supports LTI-03's potential effectiveness, showing attenuation of pro-fibrotic proteins in ex-vivo lung slices. - Enrollment is complete for Cohort 2 (high-dose LTI-03 at 5 mg BID), with topline data anticipated in the near future.
